Gelonghui, January 18 | Xintian Pharmaceutical (002873.SZ) said during a survey receiving institutional investors that the company's current key R&D projects mainly cover modules such as innovative traditional Chinese medicine drugs, traditional Chinese medicine formula granules, ancient classic recipes, and re-research on marketed products. The R&D focus has always focused on the fields of gynecology, urinary diseases, and chronic diseases with the company's rich marketing resources and strong product influence.
1. Innovative traditional Chinese medicine, ancient classic recipes: Multiple R&D projects focusing on dominant conditions are being promoted simultaneously, and both R&D modules have new product registration plans in 2024;
2. Traditional Chinese medicine formula granules: The current R&D process for national standard filing is constantly being accelerated. The company's marketing team has completed construction, and a specialized production capacity base has also been built and put into operation. Further business growth will be achieved in the future;
3. Further research on marketed products: Secondary development work is carried out in a targeted manner based on the market performance of existing marketed varieties, which plays an important role in the company's clinical research, including dosage form improvement, indication update, and product line extension.